Observational studyBMJ (Clinical research ed.)2022
Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
Observational study in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Effect of Organized Cervical Cancer Screening Programs on Incidence and Mortality: A Systematic Review and Meta-analysis.Journal of prevention (2022) · 2026Pooled it
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care.Systematic reviews · 2025Pooled it
- Health Care Policy Implementation Trial of Primary Human Papillomavirus-Based Cervical Screening in Denmark.International journal of cancer · 2026Article
- Indicators to identify cancer screening providers with suboptimal case detection: A scoping review.International journal of cancer · 2026Article
- Comparison of ThinPrep cytology and high-risk human papillomavirus testing with different triage protocols for cervical cancer screening.American journal of translational research · 2026Article
- HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices.British journal of cancer · 2025Article
- Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.International journal of cancer · 2025Article
- Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.International journal of cancer · 2025Article
- Delivering Guideline-Concordant Care for Patients With High-Risk HPV and Normal Cytologic Findings.JAMA network open · 2025Article
- Implementation of second round of HPV-based screening for cervical cancer in programmatic contexts in Argentina.Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- High risk human papillomavirus versus cytological screening over two rounds in Finnish screening programme for cervical cancer: population based cohort study.BMJ medicine · 2025Article
- Accuracy of POC testing systems for HPV screening: the importance of disease prevalence and characteristics of the screened population.Infectious agents and cancer · 2024Article
- Cervical Cancer Screening: Patient Perspectives on Transitioning to Primary High-Risk Human Papillomavirus Testing Alone.The Permanente journal · 2024Article
- Article
- RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9-year follow-up.Cancer cytopathology · 2024Article
- The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0).Journal of clinical medicine · 2024Article
- Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.British journal of cancer · 2024Review
- Cervical Cancer Screening Recommendations: Now and for the Future.Healthcare (Basel, Switzerland) · 2023Review
- Assessing artificial intelligence enabled liquid-based cytology for triaging HPV-positive women: a population-based cross-sectional study.Acta obstetricia et gynecologica Scandinavica · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesTo provide updated evidence about the risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) and cervical cancer after a negative human papillomavirus (HPV) test in primary cervical screening, by age group and test assay.
designObservational study.
settingReal world data from the English HPV screening pilot's first and second rounds (2013-16, follow-up to end of 2019).
participants1 341 584 women.
interventionsCervical screening with HPV testing or liquid based cytological testing (cytology or smear tests). Women screened with cytology were referred to colposcopy after high grade cytological abnormalities or after borderline or low grade abnormalities combined with a positive HPV triage test. Women screened with HPV testing who were positive were referred at baseline if their cytology triage test showed at least borderline abnormalities or after a retest (early recall) at 12 and 24 months if they had persistent abnormalities.
main outcome measuresDetection of CIN3+ and cervical cancer after a negative HPV test.
resultsFor women younger than 50 years, second round detection of CIN3+ in this study was significantly lower after a negative HPV screen in the first round than after cytology testing (1.21/1000
conclusionsThese data support an extension of the screening intervals, regardless of the test assay used: to five years after a negative HPV test in women aged 25-49 years, and even longer for women aged 50 years and older. The screening interval for HPV positive women who have negative HPV tests at early recall should be kept at three years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.